Piper Sandler Reiterates Overweight Rating on iTeos Therapeutics (ITOS), 'this bodes well for ITOS’ initial data in this setting'
Tweet Send to a Friend
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $34.00 price target on iTeos Therapeutics (NASDAQ: ITOS).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
